Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -11.11%45 Earnings Yield (Joel Greenblatt) % is 2.38% as of Apr. 2026, which is 76% below its 10-year median of 10.10. GuruFocus rates PBSV with a GF Scoreâ„¢ of 45/100 and a GF Valueâ„¢ of $0.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 146842.73% on this metric.
Pharma-Bio Serv's Enterprise Value for the quarter that ended in Apr. 2026 was $2.98 Mil.
Pharma-Bio Serv's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.40 Mil. Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) for the quarter that ended in Apr. 2026 was 2.38%.
The historical rank and industry rank for Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PBSV'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1185000 Med: 10.1 Max: 4035.92
Current: -16.16
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Pharma-Bio Serv was 4035.92%. The lowest was -1185000.00%. And the median was 10.10%.
PBSV's Earnings Yield (Joel Greenblatt) % is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 4.02
vs PBSV: -16.16
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Pharma-Bio Serv's Forward Rate of Return (Yacktman) % for the quarter that ended in Apr. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Pharma-Bio Serv Earnings Yield (Joel Greenblatt) % Related Terms
Pharma-Bio Serv Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Pharma-Bio Servs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Oct. 2025 is calculated as
Pharma-Bio Serv's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 2.38% mean?
Pharma-Bio Serv (PBSV) has a Earnings Yield (Joel Greenblatt) % of 2.38% as of Apr. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Pharma-Bio Serv and its competitors. This is 76% below median its historical median of 10.10. According to the industry distribution chart, Pharma-Bio Serv ranks #999999 out of 681 companies in the Healthcare Providers & Services industry.
Is Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % too high?
Pharma-Bio Serv's current Earnings Yield (Joel Greenblatt) % of 2.38% is 76% below median its 10-year median of 10.10. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 4.02. Pharma-Bio Serv's value of 2.38% is 40.8% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #999999 out of 681 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharma-Bio Serv has a GF Scoreâ„¢ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's Earnings Yield (Joel Greenblatt) % compare to HCTI and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #999999 out of 681 companies for Earnings Yield (Joel Greenblatt) %. This places Pharma-Bio Serv in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 4.02. Pharma-Bio Serv's value of 2.38% is 40.8% below this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 4.02, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 4.02, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current Earnings Yield (Joel Greenblatt) % of 2.38% is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 4.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current Earnings Yield (Joel Greenblatt) % is 2.38%, which is 76% below median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Possible Value Trap. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 2.38%, which is 76% below median its 10-year median of 10.10 and 40.8% below the Healthcare Providers & Services industry median of 4.02. Pharma-Bio Serv's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current Earnings Yield (Joel Greenblatt) % is 2.38% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
GuruFocus considers Pharma-Bio Serv to be Possible Value Trap.
Key valuation signals for PBSV:
Earnings Yield (Joel Greenblatt) %: 2.38% (76% below median its 10-year median of 10.10)
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
Industry Position: 40.8% below the Healthcare Providers & Services median (#999999 of 681)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
45GF Score
Get the complete analysis for PBSV
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
